REG - Convatec Group PLC - Capital Markets Day

ConvaTecAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260409:nRSI7126Za&default-theme=true

RNS Number : 7126Z  Convatec Group PLC  09 April 2026

Capital Markets Day

 

Convatec announces 'Accelerate' strategy to drive the next chapter of

sustainable and profitable growth

 

·    Accelerate is the evolution of our successful FISBE strategy

·    Accelerate is how we will deliver our recently upgraded medium term
guidance

 

Convatec, a leading medical products and technology company focused on
solutions for the management of chronic conditions, will today present a new
'Accelerate' strategy at a Capital Markets Day.

 

Accelerate represents an evolution of the company's previous FISBE strategy,
which transformed Convatec into a chronic care leader in each of its care
categories (Advanced Wound Care, Ostomy Care, Continence Care and Infusion
Care). Accelerate is the next chapter, underpinned by the strongest pipeline
of innovation in Convatec's history and will see accelerating sustainable and
profitable growth.

 

Accelerating growth from a position of strength

Under FISBE, Convatec pivoted to sustainable and profitable growth,
consistently delivering against strategic targets with five years of
broad-based, resilient revenue growth. Convatec now has differentiated
products winning share and significant growth opportunities across categories,
products and geographies.

 

Building on this strong foundation, Accelerate is structured around four
strategic pillars:

1.    Customer-focused growth (C): Deepening relationships with patients,
healthcare professionals, payers and business partners to support more people
living with chronic conditions; growing sales and customer loyalty, increasing
segmental share in key markets, educating medical professionals, supporting
patients and investing in the fastest growing segments - including external
innovation and M&A

2.    Technology & Innovation (T): Delivering products and services to
address existing and unmet patient needs; generating and leveraging clinical
evidence; deploying modern, standardised digital tools to drive productivity
and implementing AI applications across key domains

3.    Execution Excellence (E): Delivering right first time, on-time
on-budget, at speed and with quality; accelerating innovation cycle time;
focusing on commercial execution, further simplification and productivity and
delivering responsible business goals

4.    Culture, purpose and performance (C): Embedding purpose-led,
performance-driven leadership, performing as one team with strong engagement
and best-in-class capabilities

 

Medium-term guidance

Accelerate is how we will deliver our recently upgraded medium term guidance:

·    6-8% annual organic revenue growth, with acceleration in each
category:

·      Advanced Wound Care: Accelerating to high single-digit growth 1 
(#_ftn1)

·      Ostomy Care: Accelerating to mid/high single-digit growth

·      Continence Care: Accelerating to mid/high single-digit growth

·      Infusion Care: Accelerating to double-digit growth

·    24-26% adjusted operating margin

·    Double-digit adjusted earnings per share growth (per annum)

·    Double-digit free cash flow to equity growth (CAGR)

 

Jonny Mason, Chief Executive Officer of Convatec, commented:

"Convatec delivers innovative medical solutions to improve the lives of
millions of people living with chronic conditions. The opportunity for future
growth is substantial. Our Accelerate strategy is how we will deliver the next
chapter of Convatec's exciting story.

 

"Chronic care markets are underpinned by long-term structural growth trends
including ageing populations and the rising prevalence of chronic conditions.
This creates opportunities to serve more people living with chronic
conditions. Our innovation pipeline of new products is stronger than ever and
represents our commitment to deliver meaningful advances in patient care.

 

"Thanks to the dedication of over 10,000 colleagues who bring our forever
caring promise to life every day, we are now set to accelerate sustainable and
profitable growth."

 

Capital Markets Day details

The Capital Markets Day will take place at 2pm BST on 9 April 2026 in London.
Online registration can be found here.
(https://edge.media-server.com/mmc/p/n2va2d4t/)

 

The event will feature presentations from Convatec's Executive Leadership
Team, including detailed insights into the Accelerate strategy,
category-specific growth drivers and our innovation pipeline.

 

- ENDS -

 

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec
is a global medical products and technologies company, focused on solutions
for the management of chronic conditions, with leading positions in Advanced
Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000
colleagues, we provide products and services in around 90 countries, united by
a promise to be forever caring. Our solutions provide a range of benefits,
from infection prevention, treatment for hard to heal wounds, at-risk skin and
ulcerated tissue to supporting debilitating conditions, improved patient
outcomes and reduced care costs. Convatec's revenues in 2025 were over $2
billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To
learn more please visit http://www.convatecgroup.com
(https://www.convatecgroup.com/)

 

For further information:

Investor Relations: IR@convatec.com

Media Relations: MediaRelations@convatec.com

 

 

 1  (#_ftnref1) AWC growth guide in 2027 is M/HSD; HSD from 2028

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKZGGDNRGGVZM



            Copyright 2019 Regulatory News Service, all rights reserved